GBIM — GlobeImmune Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$8.69m
- $6.46m
Brief: Globeimmune to delist and deregister common stock from Nasdaq Capital Market
Brief: GlobeImmune reports Q1 loss per share of $0.15
Brief: GlobeImmune hires Cantor Fitzgerald to assist in review of strategic alternatives
Brief: GlobeImmune says net income of $0.9 million for three months ended September 30, 2015
Brief: GlobeImmune reports Q2 net loss of $1.3 mln
Brief: GlobeImmune engages cantor Fitzgerald as financial advisor to assist with evaluation of strategic options
Brief: GlobeImmune Celgene Corporation entered into Celgene amendment' agreement
Brief: GlobeImmune authorizes eliminating majority of positions in workforce
Reuters Insider - Nasdaq sets new all-time high
GlobeImmune, Gilead Hep B drug fails in mid-stage study (updated)
GlobeImmune, Gilead Hep B drug fails in mid-stage study
Brief: GlobeImmune says top line results from GS-4774 phase 2 trial in virally-suppressed chronic HBV patients
Brief: GlobeImmune reports qtrly loss of $1.6 mln
Brief: GlobeImmune announces program updates and financial results for full year 2014
Brief: GlobeImmune reports Q3 net loss of $6.4 mln
Brief: GlobeImmune says updated Chordoma data from phase 1 study of gi-6301 presented at connective tissue oncology society meeting